CellAct grants Mundiphamra to develop and commercialie rights to CAP7.1

CellAct Pharma GmbH (Dortmund, Germany) granted Mundipharma International Ltd. (Dublin, Ireland) worldwide rights to develop and commercialize CAP7.1 in a deal that CellAct says is valued at more than $250 million. Under the deal, CellAct will receive an undisclosed double-digit upfront payment and is eligible for milestones. CellAct and Charité-Universitätsmedizin Berlin, which discovered the drug, are eligible for double-digit royalties. ...